Shopping Cart
- Remove All
- Your shopping cart is currently empty
DCG-IV is an effective agonist of class II mGluR. DCG-IV has anticonvulsant and neuroprotective effects. The EC50 of mGlu2R and mGlu3R are 0.35 and 0.09 μM, respectively. DCG-IV is also a competitive antagonist of Group I (IC50: mGlu1 / 5R = 389/630 μM) and III receptor (IC50: mGlu4 / 6/7 / 8R = 22.5 / 39.6 / 40.1 / 32 μM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $745 | 35 days | |
10 mg | $1,590 | 35 days | |
50 mg | $6,410 | 35 days |
Description | DCG-IV is an effective agonist of class II mGluR. DCG-IV has anticonvulsant and neuroprotective effects. The EC50 of mGlu2R and mGlu3R are 0.35 and 0.09 μM, respectively. DCG-IV is also a competitive antagonist of Group I (IC50: mGlu1 / 5R = 389/630 μM) a |
Targets&IC50 | mGluR2R:0.35 μM (EC50), mGluR1R:389 μM (IC50), mGluR5:630 μM (IC50), mGluR4R:22.5 μM (IC50), mGluR7:40.1 μM (IC50), mGluR3R:0.09 μM (EC50), mGluR6:39.6 μM (IC50), mGluR8:32 μM (IC50) |
In vitro | DCG-IV is also a NMDA receptor agonist in rat cerebral cortex. |
In vivo | DCG-IV (1-10 mg / kg; i.p.) inhibits hyperactivity caused by phencyclidine (PCP). |
Molecular Weight | 203.15 |
Formula | C7H9NO6 |
Cas No. | 147782-19-2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.